Search Results

obesity and transplant outcomes in MM patients in the era of modern therapy, routine post-transplant maintenance, and genetic-based risk stratification. Methods: We retrospectively reviewed consecutive patients undergoing autoPBSCT for MM at our

Background: Despite growing recognition that patient preferences and values should inform cancer care, patients’ views continue to be under-represented. We developed a quantitative tool, Valued Outcomes in the Cancer Experience (VOICE), to measure

validated 12 – 15 ; however, it is considered a screening measure and not intended or appropriate for diagnostic purposes. Results in this study focus on outcomes regarding pain, fatigue, depression, anxiety, and well-being. Canadian Problem Checklist

focusing on composite cardiovascular outcomes. 4 – 13 Before attempting to fully understand the mechanisms behind changes in cardiovascular risk in women diagnosed with breast cancer, there is a pressing need for evidence on associations between breast

-targeted therapies, such as trastuzumab. 3 – 5 However, outcomes for patients with HER2+ breast cancer treated outside of clinical trials are limited. 6 , 7 In small, node-negative, HER2+ tumors, the benefit of adding trastuzumab to adjuvant chemotherapy

and symptom relief, another study of older adults with solid tumors starting chemotherapy suggested that older adults may value other outcomes instead of survival. 11 The role of patient preferences in NETs has not yet been studied. Clinical trials

gemcitabine-based chemotherapy, has significantly improved the outcome of patients with metastatic pancreatic cancer (MPC), increasing median overall survival (OS) to 8 to 12 months. 3 However, therapeutic options for MPC are still limited and the prognosis

survival. 10 – 14 Despite its importance for optimal outcomes, adherence to these medications varies widely, with rates ranging from as high as 100% to <50%. 15 – 18 A variety of patient-, clinician-, treatment-, and healthcare system–related factors are

potential of missing data or bias), and little attention to patients with advanced disease who received opioids for pain management rather than as a perioperative anesthetic. To provide a better assessment of the impact of opioid use on outcomes of patients

Background Approximately 65,000 new cases of head and neck cancer (HNC) are diagnosed in the United States annually, with 13,500 cancer-related deaths. 1 HNC has discrepancies in presentations and outcomes across different racial and ethnic cohorts